ACRS vs PATH · rev $18.7M vs P/E 19, rev $1.61B
Aclaris Therapeutics Inc (ACRS) versus Uipath Inc (PATH) — a side-by-side from cached financials, not a winner call.
Aclaris Therapeutics Inc (ACRS) is a biotechnology company listed on NASDAQ.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
Latest reported ACRS revenue for 2024-12-31 was $18.7M. Net income was -$132.1M. Revenue was down 40.1% from 2023-12-31 to 2024-12-31. ACRS currently screens at market cap $615.9M.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
ACRS currently screens at market cap $615.9M. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Not investment advice. Open the ACRS and PATH stock pages for the full models.
Not investment advice.